Skip to main content

AI assistant

Sign in to chat with this filing

The assistant answers questions, extracts KPIs, and summarises risk factors directly from the filing text.

Emergent BioSolutions Inc. Director's Dealing 2017

Nov 13, 2017

32870_dirs_2017-11-13_97606933-12c3-408f-879b-b62a693681eb.zip

Director's Dealing

Open in viewer

Opens in your device viewer

SEC Form 4 — Statement of Changes in Beneficial Ownership

Issuer: Emergent BioSolutions Inc. (EBS)
CIK: 0001367644
Period of Report: 2017-11-08

Reporting Person: Zoon Kathryn C (Director)

Non-Derivative Transactions

Date Security Code Shares Price A/D Holdings After Ownership
2017-11-08 Common Stock S 2371 $38.9443 Disposed 20114 Direct
2017-11-08 Common Stock S 371 $40.8446 Disposed 19743 Direct

Footnotes

F1: Consists of restricted stock units granted under the Third Amended and Restated Emergent BioSolutions Inc. 2006 Stock Incentive Plan.

F2: The restricted stock units vest in three equal annual tranches beginning in November 2017.

F3: The transactions reported in this row were effected pursuant to a Rule 10b5-1 plan adopted by Dr. Zoon.

F4: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $38.79 to $39.25, inclusive.

F5: The price reported is a weighted average price. These shares were sold in multiple transactions at prices ranging from $40.84 to $40.85, inclusive.